New hope for lung cancer patients whose tumor changes form
NCT ID NCT05957510
First seen Apr 07, 2026 · Last updated May 22, 2026 · Updated 7 times
Summary
This study tests a combination of the drug serplulimab plus chemotherapy in people whose lung cancer has changed from one type (EGFR-mutated non-small cell) to another (small cell) after prior treatment. About 66 adults aged 18-75 in China will receive the treatment to see if it slows cancer growth or shrinks tumors. The goal is to find a better way to control this aggressive cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial Perople's Hospital
RECRUITINGGuangzhou, Guangdong, China
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.